Lung deposition and systemic bioavailability of dose delivered to smoker compared with non-smoker COPD subjects.

Basma M E MohamedRanda Salah EldinAbeer Salah EldinMohamed E A Abdelrahim Raghda R S Hussein

Published in: International journal of clinical practice (2020)

The study demonstrated that smoking reduced the lung deposition of inhaled salbutamol delivered by nebulizer or pMDI. However, the smoking effect on cytochrome p450 was observed to increase systemic absorption of the ingested portion of the inhaled dose. The lower lung deposition and possible higher systemic absorption should be taken into consideration while prescribing inhaled medication to COPD smokers especially exacerbated patients that need ventilation. Further studies are needed.

Keyphrases

smoking cessation
chronic obstructive pulmonary disease
cystic fibrosis
lung function
end stage renal disease
newly diagnosed
ejection fraction
primary care
healthcare
prognostic factors
adverse drug
patient reported outcomes
intensive care unit
mechanical ventilation